Entrada Therapeutics
TRDA
97 hedge funds and large institutions have $481M invested in Entrada Therapeutics in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 19 reducing their positions, and 8 closing their positions.
163% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 8
121% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 19
110% more call options, than puts
Call options by funds: $551K | Put options by funds: $262K
15% more funds holding
Funds holding: 84 → 97 (+13)
14% more capital invested
Capital invested by funds: $423M → $481M (+$57.9M)
0.95% more ownership
Funds ownership: 79.97% → 80.91% (+0.95%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$2.55M |
| 2 |
BlackRock
New York
|
+$2.03M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.47M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$7.99M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$5.27M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.35M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.34M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.16M |
TRDA Hedge Fund Activity: Q3 2024 in Review
97 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q3 2024, worth a combined $481M — up 14% from $423M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TRDA positions and 8 closed out — a net gain of 13 holders — while 42 added to existing stakes and 19 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $2.55M. The largest seller was Redmile Group, exiting entirely with an estimated $7.99M sold.
- 97 institutional investors held Entrada Therapeutics (TRDA) as of Q3 2024, up from 84 in Q2 2024.
- Funds reported $481M of Entrada Therapeutics stock for Q3 2024, up 14% quarter-over-quarter.
- 21 funds opened new Entrada Therapeutics positions in Q3 2024 and 8 closed out, a net change of +13 holders.
- The largest Entrada Therapeutics buyer in Q3 2024 was Janus Henderson Group, an estimated $2.55M added.
- The largest Entrada Therapeutics seller in Q3 2024 was Redmile Group, an estimated $7.99M sold.
Based on aggregated 13F filings for Q3 2024.